KAS
CRSP icon

Kemnay Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Kemnay Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46K Buy
843
+76
+10% +$4.01K 0.01% 328
2026
Q1 		$36.5K Buy
767
+484
+171% +$25.5K 0.01% 372
2025
Q4 		$14.8K Buy
+283
New +$16.9K ﹤0.01% 637

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kemnay Advisory Services's CRSP Position: Q2 2026 in Review

Kemnay Advisory Services increased its CRISPR Therapeutics (CRSP) stake by 9.9% in Q2 2026, buying an estimated $4.01K and bringing the position to 843 shares worth $46K. The position accounts for 0.01% of the portfolio, ranked #328.

Kemnay Advisory Services first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Kemnay Advisory Services held 843 shares of CRISPR Therapeutics worth $46K as of Q2 2026.
  • Kemnay Advisory Services bought 76 CRISPR Therapeutics shares in Q2 2026, an estimated $4.01K.
  • CRISPR Therapeutics made up 0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #328 holding.
  • Kemnay Advisory Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.